

# New tablet-only treatment combination for AML



## STUDY OVERVIEW:

- This early study (phase I/II) tested a **new tablet-only** treatment combination of decitabine-cedazuridine and venetoclax for people **recently diagnosed with acute myeloid leukemia (AML)**
- The goal was to offer an effective treatment option that patients **could take at home** – **reducing the need for regular hospital visits**

## Who participated?


- **189 people** with AML
- **Aged over 75 years** or people with other health issues that meant they couldn't have chemotherapy

## What was studied?


New **tablet-only** combination of **decitabine-cedazuridine** and **venetoclax**



## How effective was the treatment?




had little/**no signs of cancer** in their blood or bone marrow (remission)



stayed in remission for at least **9 months**

On average people lived for **15.5 months** after treatment

## What were the most common side effects?



**Most common =**  
low levels of blood cells

**Other** side effects included:



**19%**  
felt sick



**16.4%**  
had a reduced  
appetite



**12.7%**  
had  
constipation



## WHAT DOES THIS MEAN FOR PEOPLE WITH AML?

- The results were encouraging – about half of patients had **no detectable signs of cancer** in their blood or bone marrow after treatment (remission)
- The **side effects** were as expected for this type of treatment
- This **tablet-only** treatment is still being tested but could become a more convenient at-home option for people newly diagnosed with AML, **reducing trips to the hospital**

